PHARMACOLOGY SHARED RESOURCE (Core-529) ABSTRACT Overview: An important component of drug-based studies is the assessment of drug exposure in both preclinical and clinical studies. The Pharmacology Shared Resource (PharmSR) provides a mechanism by which University of Colorado Cancer Center (UCCC) investigators can plan and carry out pharmacokinetic (PK) and pharmacodynamic (PD) studies in consultation with expert investigators. Equipment: Quantitative analytical methods offered include high performance liquid chromatography (HPLC) with UV/Vis and fluorescent detection, LC tandem mass spectrometry (LC/MS/MS), and other biochemical analysis methods (e.g. ELISA, enzymatic). Institutional support led to the purchase of an AB SCIEX QTRAP? 6500 LC/MS/MS system during the last funding period, providing state of the art technology to UCCC investigators. Services: Services offered by the PharmSR include: (1) consultation on PK study design; (2) development, validation and implementation of appropriate analytical assays for drugs in biological fluids and tissues; and (3) PK and PD modeling and mathematical analysis of analytical data. PK modeling services include systems based approaches (non- compartmental modeling), compartmental modeling, Physiologically-Based PK analyses (PBPK) and population approaches. Consultation and Education: The PharmSR provides consultation to help members with limited pharmacology or PK background to design appropriate experiments and analyze PK data. Consultations provided to members roughly equates to approximately 5 letters of support being requested annually for grant submission proposing use of the PharmSR. Management: The PharmSR is located at CSU and is an institutional core jointly managed by the UCCC and CSU. CCSG funding represents 24% of the annual operating budget. The remaining support comes from the CCTSI grant (13%) and user fees (63%). PharmSR is overseen by the Associate Director of Translational Research. Use of Services: Since July 2011, 55 investigators have used the PharmSR services. Thirty-six percent (20) were UCCC members representing four of the six UCCC programs and generating 20 peer-reviewed publications. Future Directions: The Pharm SR is currently establishing multiplex assays to directly quantitate panels of ATP-binding cassette (ABC) transporter proteins and drug metabolizing enzymes (P450s) from in vitro, preclinical and patient specimens. The goal is for the PharmSR to offer these focused proteomic assays to quantitate proteins relevant to drug development and mechanism of action.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA046934-29
Application #
9207581
Study Section
Subcommittee A - Cancer Centers (NCI-A)
Project Start
Project End
Budget Start
2017-02-01
Budget End
2018-01-31
Support Year
29
Fiscal Year
2017
Total Cost
$106,424
Indirect Cost
$13,875
Name
University of Colorado Denver
Department
Type
Domestic Higher Education
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Harder, Bryan; Tian, Wang; La Clair, James J et al. (2017) Brusatol overcomes chemoresistance through inhibition of protein translation. Mol Carcinog 56:1493-1500
Chen, Yufei; Anastassiadis, Konstantinos; Kranz, Andrea et al. (2017) MLL2, Not MLL1, Plays a Major Role in Sustaining MLL-Rearranged Acute Myeloid Leukemia. Cancer Cell 31:755-770.e6
DeRyckere, Deborah; Lee-Sherick, Alisa B; Huey, Madeline G et al. (2017) UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models. Clin Cancer Res 23:1481-1492
Scarborough, Hannah A; Helfrich, Barbara A; Casás-Selves, Matias et al. (2017) AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non-Small Cell Lung Cancer Cells Following EGFR Inhibition. Clin Cancer Res 23:1531-1541
Neelakantan, Deepika; Zhou, Hengbo; Oliphant, Michael U J et al. (2017) EMT cells increase breast cancer metastasis via paracrine GLI activation in neighbouring tumour cells. Nat Commun 8:15773
Barón, Anna E; Kako, Severine; Feser, William J et al. (2017) Clinical Utility of Chromosomal Aneusomy in Individuals at High Risk of Lung Cancer. J Thorac Oncol 12:1512-1523
Todd, Maria C; Langan, Thomas A; Sclafani, Robert A (2017) Doxycycline-Regulated p16MTS1 Expression Suppresses the Anchorage-Independence and Tumorigenicity of Breast Cancer Cell Lines that Lack Endogenous p16. J Cancer 8:190-198
Brown, Dustin G; Borresen, Erica C; Brown, Regina J et al. (2017) Heat-stabilised rice bran consumption by colorectal cancer survivors modulates stool metabolite profiles and metabolic networks: a randomised controlled trial. Br J Nutr 117:1244-1256
Haverkos, Bradley M; Abbott, Diana; Hamadani, Mehdi et al. (2017) PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood 130:221-228
Shearn, Colin T; Saba, Laura M; Roede, James R et al. (2017) Differential carbonylation of proteins in end-stage human fatty and nonfatty NASH. Free Radic Biol Med 113:280-290

Showing the most recent 10 out of 1448 publications